Effects of Combined Oral Administration and Intravenous Injection on Maintaining Decreased Systemic Tyrosine Levels in Rats

Artificial Cells, Blood Substitutes, and Immobilization Biotechnology

Volumn 32, Issue 1, 2004, Pages 129-148

  Yu, Binglan ^a   Chang, Thomas Ming Swi ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

Artificial cells; Crosslinking; Encapsulated tyrosinase; Melanoma; Polyhemoglobin tyrosinase; Tyrosine

Indexed keywords

CROSSLINKING; ENZYMES; HEMOGLOBIN; OPTIMIZATION;

TYROSINE LEVEL;

BIOTECHNOLOGY;

MONOPHENOL MONOOXYGENASE; PENTOBARBITAL; POLYHEMOGLOBIN TYROSINASE; TYROSINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTIFICIAL CELL; CONFERENCE PAPER; CONTROLLED STUDY; CROSS LINKING; DRUG DELIVERY SYSTEM; DRUG EFFECT; MALE; MELANOMA; MICROENCAPSULATION; NONHUMAN; OXYGEN AFFINITY; RAT;

ADMINISTRATION, ORAL; ANIMALS; CAPSULES; HEMOGLOBINS; INJECTIONS, INTRAVENOUS; MALE; MELANOMA; MONOPHENOL MONOOXYGENASE; OXYGEN; RATS; RATS, SPRAGUE-DAWLEY; TYROSINE;

ANIMALIA;

EID: 1442348822     PISSN: 10731199     EISSN: None     Source Type: Journal    
DOI: 10.1081/BIO-120028673     Document Type: Conference Paper

References (42)

1. Abdi, E. A., Hanson, J., McPherson, T. A. (1987). Adjuvant chemoimmunotherapy after regional lymphadenectomy for malignant melanoma. Am. J. Clin. Oncol. 10(2):117-122.
2. Bezwoda, W. R. (1997). The treatment of disseminated malignant melanoma with special reference to the role of interferons, vinca alkaloids and tamoxifen. Cancer Treat. Rev. 23(1):17-34.
3. Bourget, L., Chang, T. M. S. (1986). Phenylalanine ammonia-lyase microencapsulated in microcapsules for the depletion of phenyl alanine in plasma in phenylketonuric rat model. Biochim. Biophys. Acta 883:423-438.
4. Bourget, L., Chang, T. M. S. (1989). Effects of oral administration of artificial cells microencapsulated phenylalanine ammonia-lyase on intestinal amino acids of phenylketonuric rats. Biomater. Artif. Cells Artif. Organs 17(2):161-181.
5. Chang, T. M. S. (1972). Monograph on Artificial Cells. Springfield, IL. USA. Charles C. Thomas (free access at http://www.medicine.mcgill.ca/artcell/1972bookCover.pdf).
6. Chang, T. M. S. (1985). Artificial cells with regenerating multienzyme systems. Method. Enzymol. 112:195-203.
7. Chang, T. M. S. (1997). Monograph on Blood Substitutes: Principles, Methods, Products and Clinical Trials. Basel, New York: Karger Landes Systems (free access at: http://www.medicine.mcgill.ca/artcell/bloodsubvoll.pdf).
8. Chang, T. M. S., Bourget, L., Lister, C. (1995). A new theory of enterorecirculation of amino acids and its use for depleting unwanted amino acids using oral enzyme-artificial cells, as in removing phenylalanine in phenylketonuria. Artif. Cells Blood Substit. Immobil. Biotechnol. 25:1-23.
9. Chang, T. M. S., Prakash, S. (2001). Procedure for microencapsulation of enzymes, cells and genetically engineered microorganisms. Mol. Biotechnol. 17:249-260.
10. Charles, M. H. (2001). Monograph on Cancer Treatment. Philadelphia, USA: W.B. Saunders.
11. Cocconi, G., Bella, M., Calabresi, F., Tonato, M., Canaletti, R., Boni, C., Buzzi, F., Ceci, G., Corgna, E., Costa, P. (1992). Treatment of metastatic malignant melanoma with dacarbazine plus tamoxifen. New England J. Med. 327:516-523.
12. Cooper, J. S. (1998), The evolution of the role of radiation therapy in the management of mucocutaneous malignant melanoma. Hematol. Oncol. Clin. North Am. 849-862.
13. Demopoulos, H. B. (1966). Effects of reducing the phenylalanine-tyrosine intake of patients with advanced malignant melanoma. Cancer 9:657-664.
14. Fraker, D. L. (1999). Hyperthermic regional perfusion for melanoma and sarcoma of the limbs. Curr. Probl. Surg. 36:841-907.
15. Fronticelli, C., Bucci, E. (1994). Conformation and functional characteristics of bovine hemoglobin. Method Enzymol. 231:150-163.
16. Fronticelli, C., Bucci, E., Orth, C. (1984). Solvent regulation of oxygen affinity in hemoglobin. J. Biol. Chem. 259(17):10841-10844.
17. Fronticelli, C., Sanna, M. T., Perez-Alvarado, G. C., Karavitis, M., Lu, A. L., Brinigar, W. S. (1995). Allosteric modulation by tertiary structure in mammalian hemoglobins Introduction of the functional characteristics of bovine hemoglobin into human hemoglobin by five amino acid substitutes. J. Biol. Chem. 270(51):30588-30592.
18. Ge, X., Fu, Y. M., Li, Y. Q., Meadows, G. G. (2002). Activation of caspases and cleavage of Bid are required for tyrosine and phenylalanine deficiency-induced apoptosis of human A375 melanoma cells. Arch. Biochem. Biophys. 403:50-58.
19. Gennari, R., Bartolomei, M., Testori, A., Zurrida, S., Stoldt, H. S., Audisio, R. A., Geraghty, J. G., Paganelli, G., Veronesi, U. (2000). Sentinel node localization in primary melanoma, preoperative dynamic lymphoscintigraphy, intraoperative gamma probe, and vital dye guidance. Surgery 127:19-25.
20. Halvorsen, S., Gjessing, L. R. (1964). Studies on tyrosinosis 1. Effect of low-tyrosine and low-phenylalanine diet. British. Med. J. 2:1171-1173.
21. Lawson, D. H., Stockton, L. H., Bleier, J. C., Acosta, P. B., Heymsfield, S. B., Nixon, D. W. (1985). The effect of a phenylalanine and tyrosine restriction diet on elemental balance studies and plasma aminograms of patients with disseminated malignant melanoma. Am. J. Clin. Nutr. 41:73-84.
22. Meadows, G. G., Oeser, D. E. (1983). Response of B16 melanoma-bearing mice to varying dietary levels of phenylalanine and tyrosine. Nutr. Rep. Int. 28:1073-1082.
23. Meadows, G. G., Pierson, H. F., Abdallah, R. M., Desai, P. R. (1982). Dietary influence of tyrosine and phenylalanine on the response of B16 melanoma to carbidopa-levodopa methyl ester chemotherapy. Cancer Res. 42:3056-3063.
24. Meadows, G. G., Zhang, H., Ge, X. (2001). Specific amino acid deficiency alters the expression of genes in human melanoma and other tumor cell lines. J. Nutr. 131:3047S-3050S.
25. Meisenberg, B. (1996). High-dose chemotherapy and autologous stem cell support for patients with malignant melanoma. Bone Marrow Transplant. 17:903-906.
26. Pavey, S., Gabrielli, B. (2002). Alpha-melanocyte stimulating hormone potentiates p16/CDKN2A expression in human skin after ultraviolet irradiation. Cancer Res. 62:875-880.
27. Pyrhonen, S., Hahka-Kemppinen, M., Muhonen, T., Nikkanen, V., Eskelin, S., Summanen, P., Tarkkanen, A., Kivela, T. (2002). Chemoimmunotherapy with bleomycin, vincristine, lomustine, dacarbazine (BOLD), and human leukocyte interferon for metastatic uveal melanoma. Artif. Cells Blood Substit. Immobil. Biotechnol. 95(11):2366-2372.
28. Quan, W. D., Mitchell, M. S. (1993). Immunology and immunotherapy of melanoma. Cancer Treat. Res. 65:257-277.
29. Rosenberg, S. A., Kawakami, Y., Robbins, P. F., Wang, R. (1996). Identification of the genes encoding cancer antigens: implications for cancer immunotherapy. Adv. Cancer Res. 70:145-177.
30. Rosenberg, S. A., Lotze, M. T., Yang, J. C., Topalian, S. L., Chang, A. E., Schwartzentruber, D. J., Aebersold, P., Leitman, S., Linehan, W. M., Seipp, C. A. (1993). Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. J. Natl. Cancer Inst. 85:622-632.
31. Roses, D. F., Provet, J. A., Harris, M. N., Gumport, S. L., Dubin, N. (1985). Prognosis of patients with pathologic stage II cutaneous malignant melanoma. Ann. Surg. 201:103-107.
32. Serrone, L., Zeuli, M., Sega, F. M., Cognetti, F. (2000). Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview. J. Exp. Clin. Cancer Res. 19(1):21-34.
33. Veronesi, U., Cascinelli, N. (1991). Narrow excision (1-cm margin) A safe procedure for thin cutaneous melanoma. Arch. Surg. 126:438-441.
34. Waalkes, T. P., Udenferiend, S. (1957). A fluorometric method for the estimation of tyrosine in plasma and tissues. J. Lab. Clin. Med. 11:733-736.
35. Wolff, S. N., Herzig, R. H., Fay, J. W., LeMaistre, C. F., Frei-Lahr, D., Lowder, J., Bolwell, B., Giannone, L., Herzig, G. P. (1989). High-dose thiotepa with autologous bone marrow transplantation for metastatic malignant melanoma: results of phase I and II studies of the North American Bone Marrow Transplantation Group. J. Clin. Oncol. 7:245-249.
36. Wong, J. H., Cagle, L. A., Morton, D. L. (1987). Surgical treatment of lymph nodes with metastatic melanoma from unknown primary site. Arch. Surg. 122:1380-1383.
37. Wong, J. H., Steinemann, S., Yonehara, C., Coel, M. N., Ko, P. J., Tonaki, K., Tauchi, P. (2000). Sentinel node staging for cutaneous melanoma in a university-affiliated community care setting. Ann. Surg. Oncol. 7:450-455.
38. Yu, B., Chang, T. M. S. (2002). Artificial cells for the removal of systemic tyrosine in rats. In: Proc. Can. Fed. Biol. Soc. 45th Annu. Meet. (CFBS). 76.
39. Yu, B., Chang, T. M. S. (2002). In vitro enzyme kinetics of microencapsulated tyrosinase. Artif. Cells Blood Substit. Immobil. Biotechnol. 30:533-546.
40. Yu, B., Chang, T. M. S. (2004). Effects of long term oral administration of microencapsulated tyrosinase on maintaining decreased systemic tyrosine levels in rats. Pharmaceutical Sciences (in press).
41. Yu, B., Chang, T. M. S. In vitro and in vivo effects of polyhemoglobintyrosinase on murine B16F10 melanoma (submitted).
42. Yu, W. P., Chang, T. M. S. (1996). Submicron polymer membrane hemoglobin nanocapsules as potential blood substitutes: preparation and characterization. Artif. Cells Blood Substit. Immobil. Biotechnol. 24(3):169-183.